Global GLP-1 Analogues Market Growth 2023-2029

Global GLP-1 Analogues Market Growth 2023-2029

The global GLP-1 Analogues market size is projected to grow from US$ 2381.1 million in 2022 to US$ 3831.8 million in 2029; it is expected to grow at a CAGR of 7.0% from 2023 to 2029.

United States market for GLP-1 Analogues is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for GLP-1 Analogues is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for GLP-1 Analogues is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key GLP-1 Analogues players cover Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Jiangsu Hansoh Pharmaceutical and Shanghai Benemae Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

GLP-1 analogues are a class of medications used in the treatment of type 2 diabetes. They mimic the effects of glucagon-like peptide 1 (GLP-1), which is a hormone produced by the gut that helps regulate blood sugar levels by stimulating insulin secretion and reducing glucagon secretion.

LPI (LP Information)' newest research report, the “GLP-1 Analogues Industry Forecast” looks at past sales and reviews total world GLP-1 Analogues sales in 2022, providing a comprehensive analysis by region and market sector of projected GLP-1 Analogues sales for 2023 through 2029. With GLP-1 Analogues sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Analogues industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 Analogues landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Analogues portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global GLP-1 Analogues market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Analogues and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Analogues.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Analogues market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Exenatide
Liraglutide
Semaglutide
Dulaglutide
Other

Segmentation by application
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Jiangsu Hansoh Pharmaceutical
Shanghai Benemae Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 Analogues market?

What factors are driving GLP-1 Analogues market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1 Analogues market opportunities vary by end market size?

How does GLP-1 Analogues break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.